Get the Stockscreener App
3.92
2.49%
-0.10
Opus Genetics Inc stock is traded at $3.92, with a volume of 591.87K.
It is down -2.49% in the last 24 hours and up +0.77% over the past month.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
See More
Previous Close:
$4.02
Open:
$4.01
24h Volume:
591.87K
Relative Volume:
0.62
Market Cap:
$323.66M
Revenue:
$14.20M
Net Income/Loss:
$-49.59M
P/E Ratio:
-4.6534
EPS:
-0.8424
Net Cash Flow:
$-35.25M
1W Performance:
-7.33%
1M Performance:
+0.77%
6M Performance:
+103.11%
1Y Performance:
+250.00%
1-Day Range:
$3.835
$4.02
1-Week Range:
$3.80
$4.39
52-Week Range:
$1.04
$5.81
Opus Genetics Inc Stock (IRD) Company Profile
Name
Opus Genetics Inc
Sector
Industry
Phone
248-681-9815
Address
8 DAVIS DRIVE, DURHAM
Compare IRD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
3.92 | 323.66M | 14.20M | -49.59M | -35.25M | -0.8424 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-16-26 | Initiated | Oppenheimer | Outperform |
| Jan-20-26 | Initiated | BTIG Research | Buy |
| Dec-10-25 | Initiated | B. Riley Securities | Buy |
| Nov-25-25 | Initiated | Piper Sandler | Overweight |
| Oct-29-25 | Initiated | Wedbush | Outperform |
| Oct-16-25 | Initiated | Chardan Capital Markets | Buy |
| Apr-11-25 | Initiated | Craig Hallum | Buy |
| Nov-13-24 | Resumed | H.C. Wainwright | Buy |
View All
Opus Genetics Inc Stock (IRD) Latest News
LifeSci Capital Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Cantor Fitzgerald reiterates Opus Genetics stock rating at Overweight By Investing.com - Investing.com Canada
Price to earnings forward of Opus Genetics, Inc. – NASDAQ:IRD - TradingView
Wedbush Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Opus Genetics: Buy Rating Reiterated as Analyst Sees Pivotal OPGx-BEST1 Data as Key Catalyst; $10 Price Target Unchanged - TipRanks
Opus Genetics (IRD) Updates on Ongoing Clinical Trial for Eye Di - GuruFocus
Analysts Are Bullish on Top Healthcare Stocks: Tenet Healthcare (THC), Opus Genetics (IRD) - The Globe and Mail
Opus Genetics expects September data from gene therapy trial By Investing.com - Investing.com India
Opus Genetics expects September data from gene therapy trial - Investing.com
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results - The Manila Times
Opus Genetics Provides Update on OPGx-BEST1 Phase 1/2 Trial and Expected September Topline Data - Quiver Quantitative
Opus Genetics set to read out BEST1 gene therapy data in September - Stock Titan
Price to earnings forward of Opus Genetics, Inc. – GETTEX:R3X1 - TradingView
JonesTrading Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Opus Genetics issues 1-month pediatric gene therapy results - Ophthalmology Times Europe
Price to sales forward of Opus Genetics, Inc. – NASDAQ:IRD - TradingView
Price to book forward of Opus Genetics, Inc. – NASDAQ:IRD - TradingView
Opus Genetics reaches FDA alignment on phase 3 registrational design for OPGx-LCA5 gene therapy - Ophthalmology Times Europe
symbol__ Stock Quote Price and Forecast - CNN
Opus aligns with FDA on rare eye disease gene therapy trial - BioWorld News
A Quick Look at Today's Ratings for Opus Genetics(IRD.US), With a Forecast Between $10 to $13 - Moomoo
IRD Reiterated by BTIG -- Price Target Maintained at $12.00 - GuruFocus
IRD Maintained by Chardan Capital -- Price Target Remains at $13 - GuruFocus
B.Riley reiterates Buy on Opus Genetics stock on FDA alignment By Investing.com - Investing.com South Africa
B.Riley reiterates Buy on Opus Genetics stock on FDA alignment - Investing.com
Opus Genetics stock holds Buy rating at BTIG on gene therapy progress - Investing.com Canada
Opus Genetics aligns with FDA on Phase 3 trial for LCA5 therapy - Investing.com
Opus Genetics Reaches Alignment With US FDA on Phase 3 Trial of OPGx-LCA5 to Treat Retinal Disease - marketscreener.com
Opus Genetics aligns with FDA on Phase 3 trial for LCA5 therapy By Investing.com - Investing.com India
Opus Genetics Reaches FDA Alignment on Phase 3 Design for OPGx-LCA5; BLA May Be Submitted Based on 6-Month Data - Quiver Quantitative
Opus Genetics clears FDA design for Phase 3 trial in childhood blindness - Stock Titan
If You Invested $1,000 in Ocuphire Pharma Inc (OCUP) - Stock Titan
RBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked Setup - Yahoo Finance
Opus Genetics Advances New Gene Therapy Trial for Rare Childhood Blindness - TipRanks
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell 2500 Growth Benchmark - marketscreener.com
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell 2000 Index - marketscreener.com
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell 2000 Growth Benchmark - marketscreener.com
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell 3000E Growth Benchmark - marketscreener.com
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell Microcap Index - marketscreener.com
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell 3000E Index - marketscreener.com
Enterprise value to EBIT forward of Opus Genetics, Inc. – NASDAQ:IRD - TradingView
Enterprise value to EBIT forward of Opus Genetics, Inc. – DUS:R3X1 - TradingView
Opus Genetics Shares Rise on Addition to Russell Indexes - Moomoo
Opus Genetics, Inc. Actuals & Estimates (NASDAQ:IRD) - TradingView
Opus Genetics to join Russell 2000 and Russell 3000 indexes - Investing.com UK
Opus Genetics, Inc. Actuals & Estimates (FWB:R3X1) - TradingView
IRD Forecast — Price Target — Prediction for 2027 - TradingView
A2QG4Z Forecast — Price Target — Prediction for 2027 - TradingView
Opus Genetics to join Russell 2000 and Russell 3000 indexes By Investing.com - Investing.com Nigeria
Opus Genetics Inc Stock (IRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):